Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary-Reference-Cited by-同舟云学术

Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary

Published:2013-10-18 Issue:22 Volume:19 Page:6067-6073
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Ning Yangmin M.,Pierce William,Maher V. Ellen,Karuri Stella,Tang Sheng-Hui,Chiu Haw-Jyh,Palmby Todd,Zirkelbach Jeanne Fourie,Marathe Dhananjay,Mehrotra Nitin,Liu Qi,Ghosh Debasis,Cottrell Christy L.,Leighton John,Sridhara Rajeshwari,Ibrahim Amna,Justice Robert,Pazdur Richard

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom and France;Clinical Genitourinary Cancer;2024-08

2. Enhancing the Properties of Natural Products and Other Drugs: Deuterium: A Novel Approach;Journal of Natural Remedies;2024-03-01

3. Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review;Future Oncology;2023-11

4. GAD1 contributes to the progression and drug resistance in castration resistant prostate cancer;Cancer Cell International;2023-10-30

5. Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial;Advances in Radiation Oncology;2022-09